Diagnosis of different liver fibrosis characteristics by blood tests in non-alcoholic fatty liver disease

被引:41
|
作者
Cales, Paul [1 ,2 ]
Boursier, Jerome [1 ,2 ]
Chaigneau, Julien [2 ]
Laine, Fabrice [3 ,4 ]
Sandrini, Jeremy [5 ]
Michalak, Sophie [2 ,5 ]
Hubert, Isabelle [1 ,2 ]
Dib, Nina [1 ,2 ]
Oberti, Frederic [1 ,2 ]
Bertrais, Sandrine [2 ]
Hunault, Gilles [2 ]
Cavaro-Menard, Christine [6 ]
Gallois, Yves [7 ]
Deugnier, Yves [3 ,4 ]
Rousselet, Marie C. [2 ,5 ]
机构
[1] CHU Angers, Serv Hepatogastroenterol, F-49933 Angers 09, France
[2] Univ Angers, PRES UNAM, Lab HIFIH, Angers, France
[3] CHU, Hop Pontchaillou, INSERM, CIC 0203, Rennes, France
[4] CHU, Hop Pontchaillou, Serv Malad Foie, Rennes, France
[5] CHU Angers, Dept Pathol Cellulaire & Tissulaire, F-49933 Angers 09, France
[6] Univ Angers, PRES UNAM, Lab Ingn Syst Automatises, Angers, France
[7] CHU Angers, Lab Biochim & Biol Mol, F-49933 Angers 09, France
关键词
area of fibrosis; blood test; fractal dimension; image analysis; liver biopsy; liver fibrosis; metabolic syndrome NAFLD; LOGISTIC-REGRESSION; IMAGE-ANALYSIS; ACCURACY; MODELS; VARIABILITY; VALIDATION; BIOPSY; SYSTEM; NAFLD;
D O I
10.1111/j.1478-3231.2010.02314.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Aims: Our aim was to develop an accurate, non-invasive, blood-test-based method for identifying the main characteristics of liver fibrosis in non-alcoholic fatty liver disease (NAFLD). Methods: Fibrosis was staged according to NASH-CRN and Metavir systems in 226 patients with NAFLD. A fully automated algorithm measured the fractal dimension (FD) and the area of fibrosis (AOF). Independent predictors of diagnostic targets were determined using bootstrap methods. Results: (i) Development. Significant fibrosis defined by NASH-CRN F >= 2 was diagnosed by weight, glycaemia, aspartate aminotransferase (AST), alanine aminotransferase (ALT) and prothrombin index [area under the receiver operating characteristic (AUROC) = 0.867]; significant fibrosis defined by Metavir F >= 2 was diagnosed by weight, age, glycaemia, AST, ALT, ferritin and platelets (FibroMeter AUROC = 0.941, P < 0.005). AOF was estimated by the combination of hyaluronic acid, glycaemia, AST, ALT, platelets and prothrombin index (R-a(2) = 0.530), while FD was estimated by hyaluronic acid, glycaemia, AST/ALT, weight and platelets (R-a(2) = 0.529). (ii) Evaluation. Although NASH-CRN was a better system for fibrosis staging, Metavir staging was a better reference for blood test. Thus, the patient rate with predictive values >= 90% by tests was 97.3% with Metavir reference vs. 66.5% with NASH-CRN reference (P < 10(-3)). FibroMeter showed a significantly higher AUROC than the NAFLD fibrosis score for significant fibrosis, but not for severe fibrosis or cirrhosis, with both staging systems. Relationships between fibrosis lesions were well reflected by blood tests, e. g., the correlation between histological area and FD of fibrosis (r(s) = 0.971, P < 10(-3)) was well reflected by the relationship between respective blood tests (rs = 0.852, P < 10(-3)). Conclusions: Different characteristics of fibrosis in NAFLD can be diagnosed and quantified by blood tests with excellent accuracy.
引用
收藏
页码:1346 / 1354
页数:9
相关论文
共 50 条
  • [41] Non-invasive biomarkers of liver fibrosis in non-alcoholic fatty liver disease
    Basheer, Maamon
    Naffaa, Mohamed
    Assy, Nimer
    CLINICAL AND MOLECULAR HEPATOLOGY, 2023, 29 (02) : 398 - 400
  • [42] Emerging concepts in the detection of liver fibrosis in non-alcoholic fatty liver disease
    Armandi, Angelo
    Michel, Maurice
    Gjini, Kamela
    Emrich, Tilman
    Bugianesi, Elisabetta
    Schattenberg, Jorn M. M.
    EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, 2023, : 771 - 782
  • [43] Fibrosis progression and mortality in non-alcoholic fatty liver disease
    Elfwen, Olof
    Stal, Per
    Hultcrantz, Rolf W.
    Hagstrom, Hannes
    HEPATOLOGY, 2016, 64 : 531A - 531A
  • [44] Beyond Liver Disease: Non-Alcoholic Fatty Liver Disease and Advanced Liver Fibrosis in Kidney Disease
    Han, Eugene
    DIABETES & METABOLISM JOURNAL, 2022, 46 (04) : 564 - 566
  • [45] Ruling out fibrosis in non-alcoholic fatty liver disease
    Tavabie, Oliver D.
    BMJ-BRITISH MEDICAL JOURNAL, 2016, 355
  • [46] Liver Fibrosis in Non-alcoholic Fatty Liver Disease: From Liver Biopsy to Non-invasive Biomarkers in Diagnosis and Treatment
    Heyens, Leen J. M.
    Busschots, Dana
    Koek, Ger H.
    Robaeys, Geert
    Francque, Sven
    FRONTIERS IN MEDICINE, 2021, 8
  • [47] A protease assay that may speed the diagnosis of fibrosis in non-alcoholic fatty liver disease
    Zhang, H. E.
    Brewer, K.
    Jeffrey, G. P.
    Twigg, S. M.
    Mccaughan, G. W.
    Williams, K. H.
    Adams, L. A.
    Gorrell, M. D.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2017, 32 : 115 - 115
  • [48] Non-invasive tests of non-alcoholic fatty liver disease
    Li, Guanlin
    Zhang, Xinrong
    Lin, Huapeng
    Liang, Lilian Yan
    Wong, Grace Lai-Hung
    Wong, Vincent Wai-Sun
    CHINESE MEDICAL JOURNAL, 2022, 135 (05) : 532 - 546
  • [49] Non-invasive tests of non-alcoholic fatty liver disease
    Li Guanlin
    Zhang Xinrong
    Lin Huapeng
    Liang Lilian Yan
    Wong Grace Lai-Hung
    Wong Vincent Wai-Sun
    中华医学杂志英文版, 2022, 135 (05) : 532 - 546
  • [50] Non-alcoholic Fatty Liver Disease
    Tan, Hui-Hui
    Chang, Jason Pik-Eu
    PROCEEDINGS OF SINGAPORE HEALTHCARE, 2010, 19 (01) : 36 - 50